Skip to main content
Top
Published in: Indian Journal of Surgical Oncology 1/2014

01-03-2014 | Original Article

Role of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer

Authors: Debarshi Jana, Diptendra Kumar Sarkar, Suvro Ganguly, Shilpi Saha, Gaurisankar Sa, Asim Kumar Manna, Abhirup Banerjee, Syamsundar Mandal

Published in: Indian Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

COX-2 regulates tumour growth, invasion and metastasis in breast cancer. This study investigated the association between COX-2 expression in human breast cancer versus the expression of ER, PR, HER-2/neu, as well as its association with other established prognostic indicators like age, menopausal status, tumour size, lymph nodal status, stage, grade, NPI and histological subtype, and aims to validate the role of overexpression of COX-2 as a prognostic marker in patients with breast cancer in Indian subcontinent. In this hospital based study of 123 breast cancer patients (Group-A) and 76 female patients with benign breast disease (Group-B) attending a Comprehensive Breast Clinic at a reputed institute in Eastern India, COX-2 protein expression was measured from breast tissue using the Western Blot Technique. COX-2 mRNA expression was measured by RT-PCR Technique. ER, PR and HER-2/neu status was measured by immunohistochemistry methods. COX-2 was not expressed in the control group. The proportion of COX-2 positive tumours was significantly higher in patients of age >50 years [52(91.2 %), p < 0.01], postmenopausal status [64(90.1 %), p < 0.01], advanced stage of disease (p < 0.01), higher grade (p < 0.01), larger tumors (p < 0.01), metastatic lymph nodes (p < 0.01) and NPI ≥ 5.4 (p < 0.01). COX-2 expression was seen in ER-negative [66(95.7 %), p < 0.01], PR-negative [76(92.7 %), p < 0.01], and HER-2/neu positive tumours [29(100.0 %), p < 0.01]. Risk of COX-2 positivity was found to be 2.74 times more for postmenopausal status, 6.90 times more for large size tumours (≥ 2.5), 34.37 times more for node positive tumours, 9.26 times more with ER negative patients and 5.88 times more for PR negative patients. COX-2 expression is associated with established indicators of poor prognosis such as postmenopausal status, age >50 year, advanced stage of disease, large tumour size, higher grade, lymph node metastasis, NPI ≥ 5.4, ER negativity, PR negativity and HER-2/neu positivity. Thus, COX-2 expression implies aggressive tumour biology, and may play an important role as a prognostic marker.
Literature
1.
go back to reference Jana D, Das S, Sarkar DK, Mandal S, Maji A, Mukhopadhyay M (2012) Role of nuclear factor-κB in female breast cancer: a study in Indian patients. Asian Pac J Cancer Prev 13:5511–5515PubMedCrossRef Jana D, Das S, Sarkar DK, Mandal S, Maji A, Mukhopadhyay M (2012) Role of nuclear factor-κB in female breast cancer: a study in Indian patients. Asian Pac J Cancer Prev 13:5511–5515PubMedCrossRef
2.
go back to reference Jana D, Sarkar DK, Maji A, Chikkala BR, Hassanujjaman S, Mukhopadhyay M et al (2012) Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer? J Indian Med Assoc 110:429–433PubMed Jana D, Sarkar DK, Maji A, Chikkala BR, Hassanujjaman S, Mukhopadhyay M et al (2012) Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer? J Indian Med Assoc 110:429–433PubMed
3.
go back to reference Jana D, Mandal S, Mukhopadhyay M, Mitra D, Mukhopadhyay SK, Sarkar DK (2012) Prognostic signifcance of HER-2/neu and survival of breast cancer patients attending a specialized breast clinic in Kolkata, Eastern India. Asian Pac J Cancer Prev 13:3851–3855PubMedCrossRef Jana D, Mandal S, Mukhopadhyay M, Mitra D, Mukhopadhyay SK, Sarkar DK (2012) Prognostic signifcance of HER-2/neu and survival of breast cancer patients attending a specialized breast clinic in Kolkata, Eastern India. Asian Pac J Cancer Prev 13:3851–3855PubMedCrossRef
4.
go back to reference Sarkar DK, Jana D, Patil PS, Chaudhari KS, Chattopadhyay BK, Chikkala BR et al (2013) Role of NF-κB as a prognostic marker in breast cancer : a pilot study in Indian patients. Indian J Surg Oncol 13:0234–0238 Sarkar DK, Jana D, Patil PS, Chaudhari KS, Chattopadhyay BK, Chikkala BR et al (2013) Role of NF-κB as a prognostic marker in breast cancer : a pilot study in Indian patients. Indian J Surg Oncol 13:0234–0238
5.
go back to reference Chowa LW-C, Yip AY-S, Loo WT-Y, Lam C-K, Toi M (2008) Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 111:13–17CrossRef Chowa LW-C, Yip AY-S, Loo WT-Y, Lam C-K, Toi M (2008) Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 111:13–17CrossRef
6.
go back to reference Witton CJ, Hawe SJK, Cooke TG, Bartlett JMS (2004) Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 45:47–54PubMedCrossRef Witton CJ, Hawe SJK, Cooke TG, Bartlett JMS (2004) Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 45:47–54PubMedCrossRef
7.
go back to reference Williams CS, Mann M, Dubois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908–7916PubMedCrossRef Williams CS, Mann M, Dubois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908–7916PubMedCrossRef
8.
go back to reference Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90:423–429PubMedCrossRefPubMedCentral Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90:423–429PubMedCrossRefPubMedCentral
9.
go back to reference Zhao Y, Agarwal VR, Mendelson CR, Simpson ER (1996) Estrogen biosynthesis proximal to a breast tumour is stimulated by PGE(2) via cyclic AMP, reading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739–5742PubMed Zhao Y, Agarwal VR, Mendelson CR, Simpson ER (1996) Estrogen biosynthesis proximal to a breast tumour is stimulated by PGE(2) via cyclic AMP, reading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739–5742PubMed
10.
go back to reference Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716PubMedCrossRef Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716PubMedCrossRef
11.
go back to reference Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ (2002) Cyclooxygenase- 2 is overexpressed in HER-2 ⁄ neu-positive breast cancer—evidence for involvement of AP-1 and PEA3. J Biol Chem 277:18649–18657PubMedCrossRef Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ (2002) Cyclooxygenase- 2 is overexpressed in HER-2 ⁄ neu-positive breast cancer—evidence for involvement of AP-1 and PEA3. J Biol Chem 277:18649–18657PubMedCrossRef
12.
go back to reference Bartlett JMS, Mallon EA, Cooke TG (2003) The clinical evaluation of HER2 status, which test to use? J Pathol 99:411–417CrossRef Bartlett JMS, Mallon EA, Cooke TG (2003) The clinical evaluation of HER2 status, which test to use? J Pathol 99:411–417CrossRef
13.
go back to reference Vadlamudi R, Mandal M, Adam L, Steibach G, Mendelsohn J, Kumar R (1999) Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18:305–314PubMedCrossRef Vadlamudi R, Mandal M, Adam L, Steibach G, Mendelsohn J, Kumar R (1999) Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18:305–314PubMedCrossRef
14.
go back to reference Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62:1676–1681PubMed Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62:1676–1681PubMed
15.
go back to reference Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I, Schmitt FC (2002) Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55:429–434PubMedCrossRefPubMedCentral Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I, Schmitt FC (2002) Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55:429–434PubMedCrossRefPubMedCentral
16.
go back to reference Ciris IM, Bozkurt KK, Baspinar S, Kapucuoglu FN (2011) Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study. Pathol Res Pract 207:182–187PubMedCrossRef Ciris IM, Bozkurt KK, Baspinar S, Kapucuoglu FN (2011) Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study. Pathol Res Pract 207:182–187PubMedCrossRef
17.
go back to reference Ristimaki A, Sivula A, Lundin J et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632–635PubMed Ristimaki A, Sivula A, Lundin J et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632–635PubMed
18.
go back to reference Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C (2005) COX-2 expression in DCIS: correlation with VEGF, HER-2⁄neu, prognostic molecular markers and clinicopathological features. Histopathology 46:561–568PubMedCrossRef Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C (2005) COX-2 expression in DCIS: correlation with VEGF, HER-2⁄neu, prognostic molecular markers and clinicopathological features. Histopathology 46:561–568PubMedCrossRef
19.
go back to reference Shim JY, An HJ, Lee YH, Kim SK (2003) Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors. Mod Pathol 16:1199–1204PubMedCrossRef Shim JY, An HJ, Lee YH, Kim SK (2003) Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors. Mod Pathol 16:1199–1204PubMedCrossRef
20.
go back to reference Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr (1997) Constitutive activation of NFkappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639PubMedPubMedCentral Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr (1997) Constitutive activation of NFkappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639PubMedPubMedCentral
21.
go back to reference Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J et al (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumours. Cancer 89:2637–2645PubMedCrossRef Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J et al (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumours. Cancer 89:2637–2645PubMedCrossRef
22.
go back to reference Watanabe O, Shimizu T, Kinoshita J, Utada Y, Okabe T, Kimura K et al (2003) Expression of cyclooxygenase-2 in malignant and benign breast tumours. Anticancer Res 23:3215–3221PubMed Watanabe O, Shimizu T, Kinoshita J, Utada Y, Okabe T, Kimura K et al (2003) Expression of cyclooxygenase-2 in malignant and benign breast tumours. Anticancer Res 23:3215–3221PubMed
23.
go back to reference Denkert C, Winzer K-J, Muller B-M, Weichert W, Pest S, Kobel M et al (2003) Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease survival and overall survival in patients with breast cancer. Cancer 97:2978–2987PubMedCrossRef Denkert C, Winzer K-J, Muller B-M, Weichert W, Pest S, Kobel M et al (2003) Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease survival and overall survival in patients with breast cancer. Cancer 97:2978–2987PubMedCrossRef
24.
go back to reference Zeeneldin AA, Mohamed AM, Abdel HA, Taha FM, Goda IA, AboDeef WT (2009) Survival effects of cyclooxygenase-2 and 12-lypooxygenase in Egyptian women with operable breast cancer. Indian J Cancer 46:54–60PubMedCrossRef Zeeneldin AA, Mohamed AM, Abdel HA, Taha FM, Goda IA, AboDeef WT (2009) Survival effects of cyclooxygenase-2 and 12-lypooxygenase in Egyptian women with operable breast cancer. Indian J Cancer 46:54–60PubMedCrossRef
25.
go back to reference Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S (2002) Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 79:216–223PubMedCrossRef Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S (2002) Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 79:216–223PubMedCrossRef
26.
go back to reference Welch DR, Wei LL (1998) Genetic and epigenetic regulation of human breast cancer progression and metastasis. Endocr Relat Cancer 5:155–197CrossRef Welch DR, Wei LL (1998) Genetic and epigenetic regulation of human breast cancer progression and metastasis. Endocr Relat Cancer 5:155–197CrossRef
27.
go back to reference Kiley SC, Clark KJ, Goodnough M, Welch DR, Jaken S (1999) Protein kinase C delta involvement in mammary tumour cell metastasis. Cancer Res 59:3230–3238PubMed Kiley SC, Clark KJ, Goodnough M, Welch DR, Jaken S (1999) Protein kinase C delta involvement in mammary tumour cell metastasis. Cancer Res 59:3230–3238PubMed
28.
go back to reference Gilhooly EM, Rose DP (1999) The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol 15:267–270PubMed Gilhooly EM, Rose DP (1999) The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol 15:267–270PubMed
29.
go back to reference Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D et al (2011) Nottingham prognostic index in triple-negative breast cancer: a reliable prognostic tool? BMC Cancer 11:299PubMedCrossRefPubMedCentral Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D et al (2011) Nottingham prognostic index in triple-negative breast cancer: a reliable prognostic tool? BMC Cancer 11:299PubMedCrossRefPubMedCentral
30.
go back to reference Das S, Paul R, De U, Mukhopadhyay M (2011) The lady with raised prostate specific antigen: Do we need to worry? Asian Pac J Cancer Prev 12:2051–2053PubMed Das S, Paul R, De U, Mukhopadhyay M (2011) The lady with raised prostate specific antigen: Do we need to worry? Asian Pac J Cancer Prev 12:2051–2053PubMed
31.
go back to reference Vojtek AB, Der CJ (1998) Increasing complexity of the Ras signaling pathway. J Biol Chem 273:19925–19928PubMedCrossRef Vojtek AB, Der CJ (1998) Increasing complexity of the Ras signaling pathway. J Biol Chem 273:19925–19928PubMedCrossRef
32.
go back to reference Richards JA, Petrel TA, Brueggemeier RW (2002) Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol 80:203–212PubMedCrossRef Richards JA, Petrel TA, Brueggemeier RW (2002) Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol 80:203–212PubMedCrossRef
33.
go back to reference Subbaramaiah K, Chung WJ, Dannenberg AJ (1998) Ceramide regulates the transcription of cyclooxygenase-2—evidence forinvolvement of extracellular signal-regulated kinase c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem 273:32943–32949PubMedCrossRef Subbaramaiah K, Chung WJ, Dannenberg AJ (1998) Ceramide regulates the transcription of cyclooxygenase-2—evidence forinvolvement of extracellular signal-regulated kinase c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem 273:32943–32949PubMedCrossRef
Metadata
Title
Role of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer
Authors
Debarshi Jana
Diptendra Kumar Sarkar
Suvro Ganguly
Shilpi Saha
Gaurisankar Sa
Asim Kumar Manna
Abhirup Banerjee
Syamsundar Mandal
Publication date
01-03-2014
Publisher
Springer India
Published in
Indian Journal of Surgical Oncology / Issue 1/2014
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-014-0290-y

Other articles of this Issue 1/2014

Indian Journal of Surgical Oncology 1/2014 Go to the issue